Halozyme TherapeuticsHALO +3.19%92 PB Ratio is 40.45 as of Jun. 28, 2026, which is 55% above its 10-year median of 26.08. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.32 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Halozyme Therapeutics ranks worse than 96.59% on this metric.
The historical rank and industry rank for Halozyme Therapeutics's PB Ratio or its related term are showing as below:
HALO'
s PB Ratio Range Over the Past 10 Years
Min: 8.24 Med: 26.08 Max: 196.21
Current: 40.45
During the past 13 years, Halozyme Therapeutics's highest PB Ratio was 196.21. The lowest was 8.24. And the median was 26.08.
HALO's PB Ratio is ranked worse than 96.59% of 1232
companies
in the Biotechnology industry
Industry Median: 2.815
vs HALO: 40.45
During the past 12 months, Halozyme Therapeutics's average Book Value Per Share Growth Rate was -52.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -30.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Halozyme Therapeutics was 570.20% per year. The lowest was -39.30% per year. And the median was -5.90% per year.
Back to Basics: PB Ratio
Halozyme Therapeutics (NAS:HALO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Halozyme Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Halozyme Therapeutics (HALO) has a PB Ratio of 40.45 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Halozyme Therapeutics and its competitors. This is 55% above median its historical median of 26.08. Over the past decade, Halozyme Therapeutics' PB Ratio has ranged from 8.24 to 196.21. According to the industry distribution chart, Halozyme Therapeutics ranks #1190 out of 1232 companies in the Biotechnology industry, placing it in the top 96.6%.
Is Halozyme Therapeutics' PB Ratio too high?
Halozyme Therapeutics' current PB Ratio of 40.45 is 55% above median its 10-year median of 26.08. Over the past 10 years, this metric has ranged from a low of 8.24 to a high of 196.21. The Biotechnology industry median PB Ratio is 2.82. Halozyme Therapeutics' value of 40.45 is 1336.9% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #1190 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' PB Ratio compare to IBRX and TECH?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #1190 out of 1232 companies for PB Ratio. This places Halozyme Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.82. Halozyme Therapeutics' value of 40.45 is 1336.9% above this benchmark. Historically, Halozyme Therapeutics' own PB Ratio has ranged from 8.24 to 196.21 over the past decade. While the company's 10-year median is 26.08 vs. the industry median of 2.82, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current PB Ratio of 40.45 is 1336.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current PB Ratio is 40.45, which is 55% above median its own 10-year median of 26.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.32, compared to a current price of $74.96 — trading 17% below its estimated fair value. The current PB Ratio is 40.45, which is 55% above median its 10-year median of 26.08 and 1336.9% above the Biotechnology industry median of 2.82. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current PB Ratio is 40.45 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $74.96 is trading 17% below its estimated GF Value™ of $90.32.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
PB Ratio: 40.45 (55% above median its 10-year median of 26.08)
GF Value™: $90.32 vs. price of $74.96 (17% below fair value)
Industry Position: 1336.9% above the Biotechnology median (#1190 of 1232)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
